Short Interest & Thesis

Short Interest & Thesis

Bottom line. Reported short interest, short-sale volume, public net-short disclosures, and securities-lending indicators are all unavailable for ECLERX in the staged data — no deterministic official short-position fetcher is configured for the Indian market in this pipeline, so we cannot make any quantitative crowding or borrow-pressure call. Standing in for that, the documentary record is unusually clean for an India IT-services name: zero debt, no auditor qualifications, no material litigation, ~53.7% promoter holding with no pledges, ~23% mutual-fund ownership, and an aggressive multi-year capital-return program. The credible short thesis — to the extent one exists — is not built on a forensic or governance allegation but on macro / concentration / GenAI-substitution risk tied to the 63% top-10 client concentration, 92% US-plus-Western-Europe revenue, and 86% USD exposure that management itself flags.

1. Reported short interest — unavailable

Indian regulators (SEBI) make the SLB (Securities Lending and Borrowing) route the recognized stock-borrowing mechanism, and the F&O segment is the principal channel for directional short exposure on liquid mid-caps. Neither is staged here, so no quantitative crowding, days-to-cover, or borrow-cost number can be put on the page without manufacturing it. The right institutional answer is: short-interest positioning is not decision-useful for ECLERX in this run. What follows is the documentary substance behind any short narrative — built from the primary record — and the float / corporate-action setup that would matter if positioning data did arrive.

2. Holder structure & liquidity setup

As at 31 March 2025, founders P. D. Mundhra (26.85%) and Anjan Malik (26.84%) together held ~53.69% of the equity, with no pledges disclosed and the promoter group reported zero encumbrances [1]. Public float is anchored by domestic mutual funds (23.15%) and foreign portfolio investors (10.12%), with the ESOP Welfare Trust holding a further 1.44% [2]. Effective tradable float — after promoter, ESOP trust, and a sticky mutual-fund block — is in the ~30–35% range of outstanding shares, which is the structural backdrop against which any future reported-short figure would need to be read.

Liquidity numbers are computed from the staged NSE price tape (data/prices/daily.json), not from a corpus page, and therefore are not cited; they are flagged in the manifest's uncited_material_claims. The signal that matters for a hypothetical short setup: ~268k post-bonus shares trade daily against ~92M outstanding, so even a position equal to 1% of outstanding (~920k shares) would represent ~3.4 days of post-bonus ADV — covering would be slow but not impossible. Promoter + MF stickiness means the floating short-availability denominator is materially smaller than headline float suggests.

3. Corporate actions reshaping the setup

ECLERX is simultaneously shrinking and inflating the share count, in a sequence that confuses naive short-interest interpretation. The FY2025 tender buyback retired 1,375,000 fully-paid shares at ₹2,800 per share for ₹3,850 million [3], reducing issued and paid-up capital from ₹482.32M to ₹469.60M [4]. A further buyback was completed in January 2026, extinguishing 625,000 shares [5], and a 1:1 bonus issue went effective in March 2026 [6], roughly doubling the post-buyback share base. Any historical short-interest snapshot dated before March 2026 must be re-based for the bonus before being compared with post-bonus ADV or holder data.

A subtler signal: both founders participated in the FY25 tender buyback at the ₹2,800 price, with PD Mundhra realising ₹897.97 million and Anjan Malik ₹897.59 million of buyback proceeds [7]. This is a partial promoter monetisation through the buyback route — promoter holding percentages stayed essentially flat (within 10 bps) because the buyback was structured on a proportionate-tender basis — but it is the only "promoter cash-out" signal in the multi-year record and would be the closest thing to an insider-selling data point a short report might pull.

Aggregate five-year capital history disclosed in the FY2025 financial statements confirms: 16,913,215 bonus shares (FY22-23), buybacks of 1,375,000 shares (FY24-25) plus prior-year buybacks, against zero borrowings [8].

4. The credible short-thesis ledger

The corpus does not contain any short-seller report, activist campaign, accounting-investigation allegation, governance scandal, going-concern letter, or covenant-breach disclosure for ECLERX. What it does contain is management's own catalogue of what could go wrong — and these are the genuine pillars a thoughtful short pitch would lean on.

Citations, pillar by pillar: customer + geographic concentration are stated as primary risks in the MD&A under "Opportunities, Threats, Risk and Concerns" — 92% US/Western-Europe revenue and 63% top-10 client share — explicitly written into the risk framework [9], with the top-10 concentration falling to 59% disclosed on the Q4 FY26 call as a deliberate de-risking signal [10]. USD sensitivity is quantified at ±₹160.12M PBT impact on a ±5% USD move at FY25, and the hedge book stood at 72.58% of forecast 12-month forward USD sales [11]. GenAI / agentic AI is the longest-running framing in the multi-year record — the FY25 Chairman's letter explicitly puts GenAI "into live production environments" with platforms ContentOps, CareOps, Compliance Manager and Market360 [12], and the Technology Absorption disclosure leans on Roboworx CogniFlows as the proprietary agentic platform [13]. Contingent liabilities are sized in the notes: ₹200.39M standalone / ₹231.61M consolidated income-tax demands for FY10–FY22, ₹55.02M indirect-tax demands, with provisions of only ₹15.22M reflecting management's "remote" probability assessment [14] [15].

5. What is not there — and why that matters for a short setup

These eight items are individually defensive but cumulative: a credible forensic short thesis would need to bridge at least one of them, and the record offers no bridge. Auditor opinion: Price Waterhouse CA LLP issued a clean report — "no qualifications, reservations, adverse remarks or disclaimer … no instances of fraud reported" — with the Directors' Report explicitly restating this [16]. Going-concern / regulatory: the FY25 Directors' Report formally states there were "no significant or material orders passed by any regulatory Authority, Court or Tribunal which shall impact the going concern status" [17]. SEBI: the Corporate Governance Report confirms "no instances of non-compliance and no penalties/strictures imposed … by the Stock Exchanges or SEBI or any statutory authority in any matters related to the capital markets during the last 3 (Three) years" and "no material transactions with any of its related parties" [18]. The combined absence of debt, related-party pressure, regulatory friction, and audit qualifications means an accounting / governance short thesis would have to be sourced outside the primary record entirely.

6. Borrow pressure & peer crowding — unavailable

No securities-lending data (borrow fee, utilization, lendable supply, hard-to-borrow flag, locate friction) is staged for ECLERX. India routes covered short positions through the SLB segment of NSE/BSE and directional shorts through stock futures (where the underlying is in the F&O list), but neither set of indicators is captured by the v1 short-interest fetcher used in this run. Peer context is similarly unavailable — the indexed competitor set spans US-listed (Genpact, EXLS, HGS, Sagility — itself NSE-listed in India in late 2024), Indian-listed (Firstsource, Allsec) and Korean (ALLDIGI) names trading on different microstructures, so even if the data were present there would be no apples-to-apples peer-short comparison to make. Both modules are explicitly flagged as unavailable in the Evidence-quality table below.

7. Evidence quality

The single most important thing on this table is the first row: without reported short-interest data, this page cannot tell a PM whether ECLERX is crowded, lightly shorted, or borrow-stressed. The corpus tells us what a credible short thesis would attack — concentration, USD, GenAI substitution, attrition, tax tails — and the company's response on each. It does not tell us whether anyone is actually short the name today.